To read the full story, subscribe or sign in.

Xuanzhu Pharma acquires Combio in bid to expand biologics pipeline

Feb. 9, 2021

HONG KONG – Xuanzhu Biopharmaceutical Co. Ltd., a subsidiary of Beijing-based Sihuan Pharmaceutical Holdings Group Ltd., has acquired antibody technology firm Beijing Combio Pharmaceutical for an undisclosed amount.

BioWorld Asia Deals and M&A Bi-specific antibody China

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for July 5, 2022.

Novavax vaccine shows its chops

BioWorld

Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for July 5.

Biomarin outlines pricing strategy for costly hemophilia A gene therapy after backing from European regulators

BioWorld

The first gene therapy to treat severe hemophilia A was among the drugs recommended for European approval by regulators from the EMA’s CHMP at its monthly...

Upgrade your daily dose of biopharma and medtech news

Xuanzhu Pharma acquires Combio in bid to expand biologics pipeline